Education
About Us
Working with TipRanks
Follow Us
NeueHealth Inc (NEUE)
NYSE:NEUE
Top Page
NeueHealth Inc
(NYSE:NEUE)
Rating:51Neutral
Price Target:
$7.00
▲(2.19%Upside)
NeueHealth Inc (NEUE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$61.16M
Dividend YieldN/A
Average Volume (3M)5.35K
Price to Earnings (P/E)―
Beta (1Y)0.30
Revenue Growth-17.91%
EPS Growth83.17%
CountryUS
Employees986
SectorHealthcare
Sector Strength58
IndustryMedical - Equipment & Services
Share Statistics
EPS (TTM)-1.80
Shares Outstanding8,927,758
10 Day Avg. Volume2,732
30 Day Avg. Volume5,350
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.57
Price to Sales (P/S)0.00
P/FCF Ratio1.98
Enterprise Value/Market Cap8.11
Enterprise Value/Revenue0.13
Enterprise Value/Gross Profit2.47
Enterprise Value/Ebitda-0.64
Forecast
1Y Price Target
$7.00Price Target Upside2.19% Upside
Rating ConsensusHold
Number of Analyst Covering0
NeueHealth Inc Business Overview & Revenue Model
Company DescriptionNeueHealth Inc (NEUE) is a healthcare company focused on providing innovative solutions in the medical and wellness sectors. The company specializes in developing digital health platforms and services that aim to enhance patient care and streamline healthcare delivery. NeueHealth's core offerings include telemedicine services, healthcare data analytics, and personalized health management solutions.
How the Company Makes MoneyNeueHealth Inc generates revenue through a combination of subscription fees for its telemedicine platform, licensing fees for its healthcare data analytics tools, and service fees for personalized health management solutions. The company collaborates with healthcare providers and insurance companies to facilitate the integration of its solutions into existing healthcare systems, which enhances its market reach and revenue potential. Additionally, NeueHealth forms strategic partnerships with technology companies to co-develop and deploy cutting-edge digital health solutions, further contributing to its earnings.
NeueHealth Inc Earnings Call Summary
Earnings Call Date:May 08, 2025
(Q1-2025)
| % Change Since: 0.44%|
Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment Positive
The earnings call reflects a strong start to 2025 with significant growth in consumer base and continued profitability in adjusted EBITDA. Despite a slight decline in consolidated revenue and an operating loss in the NeueSolutions segment, the overall performance indicates positive momentum and successful implementation of a value-driven care model.Q1-2025 Updates
Positive Updates
Significant Consumer Growth
NeueHealth served over 709,000 consumers in Q1 2025, representing a growth of approximately 51% over Q1 2024.
Adjusted EBITDA Profitability
NeueHealth achieved adjusted EBITDA profitability for the fifth consecutive quarter, driving $13.5 million of adjusted EBITDA in the first quarter.
Increase in Value-Based Consumers
The NeueCare segment reported serving 530,000 value-based consumers, an increase of approximately 67% over 2024.
Diverse Population Base Mitigates Risk
By serving a diverse population across the ACA Marketplace, Medicare, and Medicaid, NeueHealth can mitigate risk associated with high concentration in any one product area.
Negative Updates
Slight Decline in Consolidated Revenue
NeueHealth consolidated revenue for the first quarter was $215.8 million, slightly lower than the prior year due to a shift in membership mix away from ACO REACH to other lines of business.
Operating Loss in NeueSolutions Segment
The NeueSolutions segment experienced an operating loss of $3 million in the first quarter.
Company Guidance
In the first quarter of 2025, NeueHealth demonstrated significant growth and strategic expansion, as discussed in their earnings call. The company reported serving 709,000 consumers, a 51% increase over the previous year, with a consolidated revenue of $215.8 million. The growth was driven by their value-driven consumer-centric care model, which enhanced relationships with consumers, providers, and payers. NeueHealth achieved an adjusted EBITDA of $13.5 million and a gross margin of $54.9 million. In the NeueCare segment, revenue reached $90.5 million with an operating income of $23 million, as they served 530,000 value-based consumers, marking a 67% increase from 2024. Meanwhile, the NeueSolutions segment generated $127.6 million in revenue but faced an operating loss of $3 million. The company continues to focus on expanding its Medicaid consumer base and leveraging innovative government programs like MSSP and ACO REACH to serve approximately 41,000 consumers. With $239.4 million in total cash and investments, NeueHealth is well-positioned to capitalize on growth opportunities in their existing and new markets while enhancing partnerships with payer groups and providers.NeueHealth Inc Financial Statement Overview
Summary
NeueHealth Inc. is facing substantial financial challenges, with negative profit margins and significant operational losses. The company's balance sheet shows financial instability with negative stockholders' equity, and cash flow issues are evident with negative operating and free cash flows.Income Statement
NeueHealth Inc. has experienced volatility in its revenue stream, with a recent decline from the previous year. Despite generating substantial total revenue of $907.3M in TTM, the company suffers from negative profit margins, with a significant net loss of $143.6M due to high operating expenses. Continued negative EBIT and EBITDA margins further reflect operational challenges.35
Negative
Balance Sheet
The balance sheet of NeueHealth Inc. reveals financial instability. The company has negative stockholders' equity of $1.36B, indicating liabilities exceed assets. With a low total debt of $1M, the debt-to-equity ratio calculation is not meaningful. The negative equity ratio and significant liabilities pose a risk to financial solvency.20
Very Negative
Cash Flow
Cash flow analysis shows negative operating cash flow of $95.5M in TTM, highlighting ongoing cash management issues. The free cash flow remains negative, further stressing the company's liquidity position. The negative cash flow to net income ratios indicate difficulties in converting earnings to available cash.30
Negative
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 907.35M | 936.66M | 1.16B | 751.16M | 1.51B | 514.89M | Gross Profit |
| 201.19M | 194.52M | 164.22M | 88.19M | 218.88M | 62.97M | EBIT |
| -81.65M | -102.06M | -577.00M | -368.76M | -343.63M | -170.38M | EBITDA |
| -97.13M | -80.76M | -566.80M | -246.39M | -308.58M | -249.31M | Net Income Common Stockholders |
| -143.64M | -134.68M | -1.15B | -1.46B | -1.18B | -248.44M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 145.10M | 93.17M | 93.56M | 217.88M | 433.76M | 988.30M | Total Assets |
| 895.68M | 544.38M | 1.23B | 4.67B | 3.60B | 1.81B | Total Debt |
| 1.00M | 204.61M | 370.35M | 303.95M | 155.00M | 28.42M | Net Debt |
| -137.10M | 121.32M | 283.05M | 86.94M | -134.28M | -459.95M | Total Liabilities |
| 1.29B | 930.49M | 1.48B | 3.73B | 2.32B | 2.27B | Stockholders Equity |
| -1.36B | -434.69M | -343.53M | 719.93M | 1.15B | -503.67M |
| Cash Flow | Free Cash Flow | ||||
| -98.84M | -125.55M | -2.73B | 207.02M | 51.65M | -63.71M | Operating Cash Flow |
| -95.55M | -123.22M | -2.73B | 234.47M | 82.06M | -57.24M | Investing Cash Flow |
| 53.57M | 186.89M | 1.12B | -429.72M | -552.89M | -689.74M | Financing Cash Flow |
| 17.38M | -253.55M | 49.91M | 1.07B | 1.04B | 712.44M |
NeueHealth Inc Technical Analysis
Positive
6.85
Price Trends
6.71
Positive
6.80
Positive
6.15
Positive
Market Momentum
0.02
Positive
54.95
Neutral
80.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NEUE, the sentiment is Positive. The current price of 6.85 is above the 20-day moving average (MA) of 6.81, above the 50-day MA of 6.71, and above the 200-day MA of 6.15, indicating a bullish trend. The MACD of 0.02 indicates Positive momentum. The RSI at 54.95 is Neutral, neither overbought nor oversold. The STOCH value of 80.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NEUE.
NeueHealth Inc Risk Analysis
NeueHealth Inc disclosed 59 risk factors in its most recent earnings report. NeueHealth Inc reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
NeueHealth Inc Peers Comparison
Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $2.75B | 17.41 | 20.83% | 1.17% | ― | ― | |
65 Neutral | $87.60M | ― | 21.00% | ― | -0.45% | 94.32% | |
54 Neutral | $5.37B | 3.26 | -45.10% | 3.30% | 16.81% | 0.02% | |
51 Neutral | $61.16M | ― | 84.03% | ― | -17.91% | 83.17% | |
51 Neutral | $56.20M | ― | -67.86% | ― | 0.34% | 6.20% | |
48 Neutral | $52.41M | ― | 678.24% | ― | -69.59% | ― | |
40 Underperform | $74.40M | ― | -157.73% | ― | 104.78% | 40.41% |
* Healthcare Sector Average
Performance Comparison
NEUE
NeueHealth Inc
6.85
1.52
28.52%
CCLD
CareCloud
2.07
-0.26
-11.16%
AVTX
Avalo Therapeutics
4.84
-6.63
-57.80%
CBUS
Cibus
1.48
-7.91
-84.24%
HYPR
Hyperfine
0.72
-0.13
-15.29%
CON
Concentra Group Holdings Parent, Inc.
21.45
-1.21
-5.34%
NeueHealth Inc Corporate Events
Executive/Board ChangesShareholder Meetings
NeueHealth Inc Holds Annual Stockholders Meeting
Neutral
May 30, 2025
On May 29, 2025, NeueHealth, Inc. held its annual meeting of stockholders where several key decisions were made. The stockholders elected ten directors to serve until the 2026 annual meeting, ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and approved the executive compensation for 2024 on a non-binding, advisory basis.
The most recent analyst rating on (NEUE) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on NeueHealth Inc stock, see the NEUE Stock Forecast page.
M&A TransactionsShareholder Meetings
NeueHealth Inc Approves Merger with NH Holdings
Neutral
May 8, 2025
On May 7, 2025, NeueHealth, Inc. held a special meeting of stockholders to consider proposals related to a merger agreement with NH Holdings 2025, Inc. and its subsidiary. The merger will result in NeueHealth becoming a wholly owned subsidiary and no longer a public company. The proposals, including the merger agreement, adjournment, and merger-related compensation, were approved by the stockholders, indicating a significant shift in the company’s structure and ownership.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.